Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCERTO: BLU-451 in advanced EGFR Exon 20-mutated cancers
NCT05241873Phase 1Terminated
- Sponsor
- Blueprint Medicines
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 1, open-label trial of BLU-451 in non-small cell lung cancer (NSCLC) and solid tumor (10 arms), sponsored by Blueprint Medicines. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 2 more. Started Mar 2022; status: terminated.
02
Drugs
BLU-451
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT05241873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241873.